Metabolic and Clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind randomized placebo-controlled clinical trial
Background: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the effects of Bunium Persicum (BP) on serum glucose indices, lipid profile, and nesfatin-1 levels in overweight or obese T2DM patients.
Methods: Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Based on the eligibility criteria, 60 participants were randomly divided into two groups, namely BP (n=30) and placebo (n=30). The supplementation was one 1000 mg capsule 2 times /day BP with meals (lunch and dinner) for 8 weeks. Bodyweight, waist circumference, serum nesfatin-1, fasting blood sugar (FBS) and insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Quantitative insulin sensitivity checks index (QUICKI), homeostasis model assessment-insulin resistance (HOMA-IR), and Body Mass Index (BMI) were also calculated.
Results: In comparison with placebo, BP significantly decreased FBS, HOMA-IR, and BMI (P<0.05). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant (P>0.05).
Conclusion: BP supplement improved serum glucose indices and decreased BMI among overweight or obese T2DM patients; though, further trials are suggested to confirm results.
Trial Registration: Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https://irct.ir/trial/35752
Figure 1
Posted 12 Jun, 2020
On 26 Aug, 2020
On 15 Jun, 2020
On 09 Jun, 2020
On 08 Jun, 2020
On 08 Jun, 2020
On 21 May, 2020
Received 19 May, 2020
On 03 May, 2020
Received 03 May, 2020
On 02 May, 2020
Invitations sent on 25 Apr, 2020
On 23 Apr, 2020
On 22 Apr, 2020
On 22 Apr, 2020
On 21 Mar, 2020
Received 08 Mar, 2020
On 25 Feb, 2020
Received 02 Feb, 2020
On 31 Jan, 2020
Invitations sent on 29 Jan, 2020
On 27 Jan, 2020
On 26 Jan, 2020
On 23 Jan, 2020
On 21 Jan, 2020
Metabolic and Clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind randomized placebo-controlled clinical trial
Posted 12 Jun, 2020
On 26 Aug, 2020
On 15 Jun, 2020
On 09 Jun, 2020
On 08 Jun, 2020
On 08 Jun, 2020
On 21 May, 2020
Received 19 May, 2020
On 03 May, 2020
Received 03 May, 2020
On 02 May, 2020
Invitations sent on 25 Apr, 2020
On 23 Apr, 2020
On 22 Apr, 2020
On 22 Apr, 2020
On 21 Mar, 2020
Received 08 Mar, 2020
On 25 Feb, 2020
Received 02 Feb, 2020
On 31 Jan, 2020
Invitations sent on 29 Jan, 2020
On 27 Jan, 2020
On 26 Jan, 2020
On 23 Jan, 2020
On 21 Jan, 2020
Background: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the effects of Bunium Persicum (BP) on serum glucose indices, lipid profile, and nesfatin-1 levels in overweight or obese T2DM patients.
Methods: Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Based on the eligibility criteria, 60 participants were randomly divided into two groups, namely BP (n=30) and placebo (n=30). The supplementation was one 1000 mg capsule 2 times /day BP with meals (lunch and dinner) for 8 weeks. Bodyweight, waist circumference, serum nesfatin-1, fasting blood sugar (FBS) and insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Quantitative insulin sensitivity checks index (QUICKI), homeostasis model assessment-insulin resistance (HOMA-IR), and Body Mass Index (BMI) were also calculated.
Results: In comparison with placebo, BP significantly decreased FBS, HOMA-IR, and BMI (P<0.05). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant (P>0.05).
Conclusion: BP supplement improved serum glucose indices and decreased BMI among overweight or obese T2DM patients; though, further trials are suggested to confirm results.
Trial Registration: Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https://irct.ir/trial/35752
Figure 1